,11 Furthermore, loss-of-function or loss-of-expression mutations of SOST (sclerostin), a secreted antagonist that prevents WNTs from binding to LRP5, cause high bone mass in sclerosteosis or Van Buchem disease, respectively.12 The gene discussed is SOST; the disease is sclerosteosis.